Sergio; BIPH do you think this may return BIPH to the up mode.
Biophan and New Scale Announce Issuance of Fundamental U.S. Patent for New Scale's SQUIGGLE(TM) Motor; Biophan Also Details New $1 Million Equity Investment by Biomed Solutions
ROCHESTER, N.Y., Sep 08, 2005 (BUSINESS WIRE) --
Biophan Technologies, Inc. (OTCBB:BIPH), a developer of next-generation biomedical technology, and New Scale Technologies, Inc., a developer of miniature ceramic motors, have announced that the U.S. Patent and Trademark Office has granted New Scale Technologies a fundamental patent for its revolutionary SQUIGGLE motor. Made of piezoelectric ceramics and other non-magnetic materials, the tiny SQUIGGLE motor has applications in numerous industries. Biophan holds exclusive worldwide distribution rights for all medical applications.
Biophan and New Scale expect the SQUIGGLE motor's novel design to set new standards for precision and reliability for such applications as implantable and wearable drug-delivery pumps. Since the motor is also safe and image-compatible for use in Magnetic Resonance Imaging (MRI) systems, Biophan and New Scale believe that the motor will enable the creation of novel MRI-compatible biomedical devices. It is also compatible with high vacuum and ultra-cold environments required in advanced applications.
"Now that the U.S. Patent office has issued the fundamental U.S. patent for the SQUIGGLE motor, Biophan and New Scale hold key intellectual property protection as we continue to develop products based on the SQUIGGLE motor," said Michael Weiner, Biophan CEO. "We believe the motor's unique features and capabilities will allow the development of significantly improved solutions for existing multi-billion-dollar health care markets, as well as the development of applications for promising new product areas in medical technology."
The SQUIGGLE motor is constructed completely of non-magnetic ceramics and other advanced materials, and is both totally safe and accurately imageable within Magnetic Resonance Imaging (MRI) systems. MRI compatibility enables the development of remote-controlled robotic surgical devices for MRI-guided procedures that require highly precise positioning under real-time visual control, such as intra-cranial procedures to treat brain tumors.
The piezoelectric ceramic SQUIGGLE motor occupies a unique niche in the world of small motors for biomedical and other industry sectors. Using ultrasonic vibrations, it delivers superior precision and electrical efficiency compared to conventional electromagnetic motors. Benefits for medical devices include low heating, low noise, high precision and longer battery life.
The SQUIGGLE motor is constructed from only four parts--about 90% fewer than many comparable electromagnetic motors with gears. Because they require no gear reduction, a significant source of failure is eliminated, increasing the SQUIGGLE motor's dependability. New Scale is producing a variety of SQUIGGLE models, ranging in size from 4 mm in diameter to 12 mm in diameter, with a variety of ranges of motion. The newest SQUIGGLE model, the SQ-306, is 50% smaller than the Company's previous models. A photo can be viewed at biophan.com.
The SQUIGGLE motor is also being developed for a number of important applications in sectors other than medicine, where its ultra-precise movement and small size is an advantage, such as automatic camera zoom lenses for cell phones and other active optical markets.
In addition to its license of New Scale's SQUIGGLE for all medical applications, Biophan is also a minority equity owner in New Scale Technologies. New Scale currently sells a range of miniature motors and positioning systems for emerging applications in nanotechnology, microelectronics, optics, lasers, biotechnology, medical devices, aerospace and defense, fluid control, and office/consumer products. (View "Biophan and New Scale Present Ceramic Motor for Medical Devices" video at biophan.com
In other new developments, Biophan announced that Biomed Solutions LLC, a longtime investor and supporter of Biophan, has made a $1 million equity investment in Biophan. Biophan's CEO, Michael Weiner, is the Manager of Biomed Solutions. The investment represents the conversion of a portion of a recently announced $2 million credit facility from Biomed Solutions. The conversion price of $2.12 is calculated at 90% of the average share price for the 20 trading days prior to the date of the loan.
Allan |
